MS drug Gilenya prescriptions slowing

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

MS drug Gilenya prescriptions slowing

Postby MSUK » Wed Jul 04, 2012 12:29 am

MS drug Gilenya prescriptions slowing due to lack of monitoring facilities

Image


Novartis’ multiple sclerosis (MS) pill Gilenya faces slowing prescriptions in New York because of a lack of facilities to perform first-dose observations, neurologists told Biopharm Insight. However, Novartis has been in contact with a number of clinicians and is working on increasing the number of sites.

A US Food and Drug Administration (FDA) review was initiated after a patient died within 24 hours of taking the first dose of Gilenya. Regulatory authorities also re-evaluated study data regarding the drug’s effect on heart rate and blood pressure.

Gilenya is now contraindicated for use in patients with certain pre-existing or recent heart conditions or stroke, or those taking certain antiarrhythmic drugs, according to FDA. Extended monitoring is recommended in patients with QT prolongation and in patients who are already taking medication that slows heart rate. Observation includes continuous overnight electrocardiography (ECG) monitoring.

A Novartis spokesperson said via email the company is committed to helping healthcare providers implement the updated prescribing information recommendations.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... geid/1309/
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2211
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service